Table III.

Characteristics of the studies included in the quantitative analysis

Reference	Country	Age (years)	Sex (female/male)	Study design	Disease	Variable studied	Treatment ingredient	Control ingredient	n total	n treatment total	n controls total
Enshaieh et al, 200633	Iran	Range: 15-25	47/13	Double-blind clinical trial	Acne	TLC	TTO	Vehicle gel	60	30	30
Kwon et al, 201434	South Korea	Mean: 25.9 ± 5.6	23/11∗	Prospective double-blind randomized controlled split-face trial	Acne	TLC	TTO	LFCO	32	32	32
Sharquie et al, 200635	Iraq	Range: 14-22 Mean: 17.8 ± 3.3	35/25∗	Single-blind, randomly controlled therapeutic study	Acne	TLC	GT	Control solution made of 75 mL distilled water and 25 mL ethanol	49	25	24
Sharquie et al, 200836	Iraq	Range: 13-27 Mean: 19.5 ± 3.5	29/11	Single-blind, randomly comparative therapeutic clinical trial	Acne	TLC	GT	Control solution made of 5% zinc sulfate	40	20	20
Yoon et al, 201337	South Korea	Mean: 22.1	18/17	Randomized, split-face, clinical trial	Acne	TLC	GT	Vehicle control	35	17 (used the 1% GT)† 18 (used the 5% GT)	35
Lu et al, 201638	Taiwan	Range: 25-45	64/0	Randomized, double-blind, placebo-controlled clinical trial	Acne	TLC	GT	Placebo (cellulose)	64	33	31
Msika et al, 200839	France	Range: 4-48 months Mean: 16 months	41/45	RCT, multicenter study	AD	SCORAD	SSO	TCS	86	53	33
Dwiyana et al, 201940	Indonesia	Range: 7-12	13/7	Randomized, double-blind trial	AD	SCORAD	SSO	Common moisturizer lotion	20	9	11
Lisante et al, 201713	USA	Mean: 8.1 ± 3.96	49/41∗	Randomized, double-blind, two-arm trial	AD	EASI	CO	Prescription barrier cream	68	31	37
Syed et al, 199641	USA	Range: 18-50 Mean: 25.6	24/36	Double-blind, placebo-controlled study	Psoriasis	PASI	AV	Vehicle gel containing castor and mineral oil	60	30	30
Paulsen et al, 200542	Denmark	Range: 23-77 Median: 44	14/26	Single-center, double-blind, placebo-controlled, rand-omized, intraindividual right/left comparison	Psoriasis	PASI	AV	Vehicle gel	40	40	40
Choonhakarn et al, 201043	Thailand	Range (treatment): 27-65; Mean: 43.4 ± 11.2 Range (control): 23-71; Mean: 44.2 ± 13.0	39/36	Randomized, comparative, double-blind study	Psoriasis	PASI, DLQI	AV	TA	75	37	38
Sarafian et al, 201344	Iran	Range: 18-60 Mean: 31.7	14/20	Randomized, prospective intraindividual, right-left comparative, placebo-controlled, double-blind pilot study	Psoriasis	PASI	Turmeric	Vehicle gel	34	34	34
Shathirapathiy et al, 201545	India	Range: 20-60 Mean (treatment): 40.81 ± 13.39 Mean (control): 32.33 ± 8.70	20/40	Parallel-group RCT	Psoriasis	PASI	Turmeric	Naturopathy interventions including massage, yoga, hydro, diet therapy	60	30	30
Bahraini et al, 201846	USA	Range (treatment): 27-35 Range (control): 29-50	21/9	Randomized, double-blind, placebo-controlled prospective clinical trial	Scalp Psoriasis	PASI	Turmeric	Placebo tonic	73	15	15

AD, Atopic dermatitis; AV, aloe vera; CO, colloidal oatmeal; EASI, eczema area and severity index; GT, green tea; LFCO, lactobacillus-fermented C. obtusa; PASI, psoriasis area and severity index; RCT, randomized controlled trial; SCORAD, severity scoring of atopic dermatitis; SSO, sunflower seed oil; TA, triamcinolone acetonide; TCS, topical corticosteroid; TLC, total lesion count reduction; TTO, tea tree oil; USA, United States of America.

^∗Indicates that the sex ratio is not representative of patients who dropped out of the study.

^†Only the 1% GT group was analyzed as the treatment group in the quantitative analysis.